Changes in Prostate Specific Antigen Levels During Synergo Therapy-Intravesical Chemotherapy Instillations Combined With Hyperthermia

HaEmek Medical Center, Israel

Overview

PURPOSE: We determined whether Synergo therapy- intravesical chemotherapy instillation combined with hyperthermia instillation is associated with elevated prostate specific antigen (PSA). MATERIALS AND METHODS: We will treat 25 consecutive patients with bladder cancer with a 6-week course of Synergo therapy, followed by cystoscopy at 6 weeks. Blood samples for PSA determination will obtain before each synergo therapy application and at cystoscopy with each patient also serving as a control. Evaluating changes in PSA level in patients undergoing treatment with Synergo delivered local hyperthermia combined with intravesical instillation of Mitomycin C for adjuvant treatment or pt. with recurrent tu of bladder post TURT with BCGtreatment.

Study Type

OBSERVATIONAL

Conditions

Bladder Cancer

Interventions

SYNERGODEVICE

SYNERGO-intravesical chemotherapy instillation combined with hyperthermiaDEVICE

Eligibility

Sex: MALEMin age: 30 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Recurrent transitional cell carcinoma of urinary bladder post endoscopic resection * PSA Prior synergo therapy application\<10 * Normal rectal examination * Patients willing to sign informed consent according Exclusion Criteria: * History of prostate cancer * Previous history of TCC stage T2 or higher * Invasive tu of bladder * Prior pelvic radiotherapy or systemic chemotherapy * Active prostatitis * Active tuberculosis

Locations (2)

Haemek MC

Afula, Israel

Department of urology

Afula, Israel

Central Contacts

doron perez, M.D.

CONTACT

+972-4-6495115 perez_do@clalit.org.il

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.